Last checked at 11 Apr 2024 17:13
FTSE 100 edges lower as financials drag
Lok'nStore surges to all-time high after buyout by Shurgard
*Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Astrazeneca Share News (AZN)
AZN Share
Price
AZN Share
News
AZN Share
Chat
AZN Share
Trades16,417
AZN
Live RNS
AZN Share
Charts
AZN Level 2
Console
AZN Live
Share Price
AZN Broker
Ratings
AZN Directors
Deals
AZN Financial
Diary
AZN
Fundamentals
AZN Short
Positions
AZN
Media
Astrazeneca Information
Share Price Information for Astrazeneca (AZN)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
12,050.00
Bid:
12,038.00
Ask:
12,040.00
Change:
-106.00 (-0.87%)
Spread:
2.00 (0.017%)
Open:
12,092.00
High:
12,178.00
Low:
12,010.00
Prev. Close:
12,156.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.London pre-open: Flat start predicted for FTSE
Mon, 29th Sep 2014 07:42
London's blue chips are set to open flat on Monday morning ahead of a very busy week both at home and abroad, particularly in the latter half. City sources predict the FTSE 100 will open unchanged from Friday's close of 6,649."European markets are set for an incredibly busy week as we see the first week of the new month," said Alpari market analyst James Hughes.He continued: "The story overnight is yet again the strength of the US dollar as Asian markets fell led by a thrashing in Hong Kong [...] However, if anything is going to shift investor opinion about the dollar it could well be this week as the data is incredibly heavy."This afternoon we will get the release of the personal consumption numbers as well as pending home sales figures. Investors will be yet again looking for any kind of positive number that could force Janet Yellen's hand into an earlier rate hike." In company news, emerging markets focused asset manager Aberdeen saw assets under management (AuM) rise by 3% in the two months to 31 August, as the rate of net outflows moderated considerably. Net outflows over the last two months amounted to just £1.7bn, after a drain of £8.8bn in the two months prior. The largest decrease in AuM was seen at Aberdeen's fixed income unit. Executives at the fund manager also highlighted that the integration of Scottish Widows Investment Partnership (SWIP) was progressing as scheduled.Despite the on-going, yet limited, disruptions to trading as a result of the 'sequestration' of US federal government expenditure, defence contractor BAE Systems maintained its full-year earnings outlook. In its latest interim management statement for the three months ended 28 September, the group revealed that its order intake for the year to 23 August was at £7.9bn, with £2.6bn of that originating from non-UK/US markets.Astrazeneca has presented data relating to various cancer treatment studies at the 2014 European Society of Medical Oncology Congress. "We are encouraged by the results we are seeing and look forward to providing further updates as we continue to work at pace to get these potentially life-changing medicines to patients," the drugs group said.
More News
11 Apr 2024 17:07
Banks weigh down Europe's STOXX 600 after ECB signals rate cuts
Outlook hike sends Ambu shares up
*Read more11 Apr 2024 15:56
London close: Stocks finish lower as ECB stands pat
(Sharecast News) - London's stock markets finished in negative territory on Thursday, as investors reacted to the European Central Bank's latest policy announcement and a producer price index release in the United States.
Read more11 Apr 2024 11:50
LONDON MARKET MIDDAY: Europe takes hit on nerves ahead of ECB decision
(Alliance News) - European equities sunk lower at midday on Thursday, with sentiment hurt by hotter-than-expected inflation from the US crushing hopes of interest rate cuts.
Read more11 Apr 2024 08:56
TOP NEWS: Astra plans 7% dividend hike for 2024 after no rise in 2023
(Alliance News) - AstraZeneca PLC said it intends to raise its annualised dividend for 2024, citing confidence in its business performance and cash generation.
Read more11 Apr 2024 08:54
LONDON MARKET OPEN: European markets mixed ahead of ECB decision
(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.
Read more11 Apr 2024 07:49
LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance
(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.
Read more11 Apr 2024 07:20
AstraZeneca to hike 2024 dividend by 7%
(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.
Read more8 Apr 2024 08:36
TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris
(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.
Read more8 Apr 2024 07:43
LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack
(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.
Read more8 Apr 2024 07:02
AstraZeneca's Enhurtu cancer gets US green light for adult patients
(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.
Read more8 Apr 2024 06:53
TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval
(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.
Read more5 Apr 2024 09:42
AstraZeneca makes "breakthrough" in treating small cell lung cancer
(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.
Read more5 Apr 2024 07:50
LONDON BRIEFING: Shell to book USD600 million first-quarter write-off
(Alliance News) - London's FTSE 100 is called to open lower on Friday, with hawkish remarks from Federal Reserve policymakers and fears of ratcheting Middle East tensions giving investors little to cheer about ahead of the latest US jobs data.
Read more5 Apr 2024 07:23
AstraZeneca announces positive lung cancer treatment trial results
(Sharecast News) - AstraZeneca announced positive high-level results from a phase three trial demonstrating significant advancements in the treatment of limited-stage small cell lung cancer (LS-SCLC) on Friday.
Read more